Translating Asian-Dominant Pivotal Evidence Into EU Marketing Authorization: An EMA Regulatory Document Analysis, 2021-2025. [PDF]
Boruah P, Zwiers A.
europepmc +1 more source
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin<sup>®</sup> and US-Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. [PDF]
Kim T +6 more
europepmc +1 more source
The biologics manufacturing patent notice challenge: a comparative examination. [PDF]
Jefferson OA, Rai A.
europepmc +1 more source
Risk management in the distribution process of biosimilar products in the pharmaceutical industry
openaire +1 more source
Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco. [PDF]
Errihani H +11 more
europepmc +1 more source
Development and preliminary physicochemical characterization of a Ramucirumab biosimilar candidate in CHO cells using shake-flask fed-batch culture. [PDF]
Cagatay E +3 more
europepmc +1 more source
Similarity assessment of disulfide isoform profiles between the romosozumab biosimilar and the reference medicinal product. [PDF]
Zhao D +11 more
europepmc +1 more source
Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars. [PDF]
Mendelsohn AB +5 more
europepmc +1 more source
Related searches:
Objective To evaluate the safety in the interchangeability of biosimilar products approved for cancer treatment from a pharmaceutical perspective. Methods A literature review was carried out using the descriptors “Biosimilar ...
Iago Dillion Lima Cavalcanti +1 more
exaly +3 more sources

